Padsevonil (UCB0942) Disease area studied Abbreviated title Phase Study ID Registry database Study results Plain language summary Publication (if available) Epilepsy Double-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety/Tolerability, and Pharmacokinetic Profile of UCB0942 in Adults With Highly Drug-resistant Focal Epilepsy. Phase 2 EP0069 Completed NCT024958442014-003330-12 LINKLINK Van Paesschen W. [abstract 1.289] available on Annual Meeting Abstract Database www.aesnet.org Epilepsy An open-label, multicenter, extension study to evaluate the long-term safety, tolerability, and efficacy of UCB0942 when used as adjunctive therapy for partial-onset seizures in adult subjects with highly drug-resistant focal epilepsy Phase 2 Phase 2 EP0073 Terminated NCT026250902015-001268-20 LINKLINK Epilepsy The purpose of the study is to characterize the dose-response relationship with respect to efficacy of Padsevonil administered concomitantly with up to 3 anti-epileptic drugs (AEDs) for treatment of observable focal-onset seizures in subjects with drug-resistant epilepsy Phase 2 EP0091 Completed NCT033733832017-003200-48 LINKLINK Werhahn K.J., et al [abstract 130] 74th Annual Meeting of the American Epilepsy Society (AES), December 04-08, 2020; Online www.aesnet.org Epilepsy A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy (DUET) Phase 3 EP0092 Completed NCT037398402018-002303-33 LINKLINK Epilepsy Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy Phase 2/3 EP0093 Terminated NCT033701202017-003241-26 LINKLINK
